Endogenous or exogenous coagulation factor level and the response to activated protein C

Thrombosis Research

Volumn 118, Issue 2, 2006, Pages 269-273

  Gennari, Laura C ^a   Blanco, Alicia N ^a   Domínguez, Maria P ^a   Grosso, Silvia H ^a   Lazzari, Maria A ^a  

^a INST DE INVEST HEMATOLOGICAS   (Argentina)

Author keywords

Activated protein C resistance; Coagulation factors; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; PROTHROMBIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACTIVATED PROTEIN C RESISTANCE; ANALYTIC METHOD; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EVALUATION; HEMOSTASIS; HUMAN; LINEAR REGRESSION ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PURIFICATION; THROMBOGENESIS;

ACTIVATED PROTEIN C RESISTANCE; DEAMINO ARGININE VASOPRESSIN; FACTOR VIII; FACTOR X; HEMOSTATICS; HUMANS; PROTEIN C; PROTHROMBIN;

EID: 33744529518     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.07.022     Document Type: Article

References (23)

1. Dahlbäck B., Carlsson M., and Svensson P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90 (1993) 1004-1008
2. Dahlbäck B. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation. Semin Thromb Hemost 25 (1999) 273-289
3. Bertina R.M. Molecular risk factors for thrombosis. Thromb Haemost 82 (1999) 601-609
4. Esmon N.L., Safa O., Smirnov M.D., and Esmon C.T. Antiphospholipid antibodies and the protein C pathway. J Autoimmun 15 (2000) 221-225
5. Henkens C.M.A., Bom V.J.J., and van der Meer J. Sensitivity to activated protein C; influence of oral contraceptives and sex. Thromb Haemost 73 (1995) 402-404
6. Laffan M.A., and Manning R. The influence of factor VIII on measurement of activated protein C resistance. Blood Coagul Fibrinolysis 7 (1996) 761-765
7. Tripodi A., Chantarangkul V., and Mannucci P.M. Hyperprothrombinemia may result in acquired activated protein C resistance. Blood 96 (2000) 3295-3296
8. de Visser M.C.H., Rosendaal F.R., and Bertina R.M. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 93 (1999) 1271-1276
9. Gennari L., Blanco A., Bermejo E., Salviú J., Grosso S., and Lazzari M.A. Activated protein C (APC) resistance: considerations about the importance of using the original and modified methods in thrombophilic disease. Thromb Haemost 84 (2000) 138-139
10. Henkens C.M.A., Bom V.J.J., and van der Meer J. Lowered APC-sensitivity ratio related to increased factor VIII-clotting activity. Thromb Haemost 74 (1995) 1198-1199
11. Smirnov M., Safa O., Esmon N., and Esmon C.T. Inhibition of activated protein C anticoagulant activity by prothrombin. Blood 94 (1999) 3839-3846
12. Rosendaal F.R. High levels of factor VIII and venous thrombosis. Thromb Haemost 83 (2000) 1-2
13. Poort S.R., Rosendaal F.R., Reitsma P.H., and Bertina R.M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88 (1996) 3698-3703
14. van Hylckama Vlieg A., van der Linden I.K., Bertina R.M., and Rosendaal F.R. High levels of factor IX increase the risk of venous thrombosis. Blood 95 (2000) 3678-3682
15. Meijers J.C., Tekelenburg W.L., Bouma B.N., Bertina R.M., and Rosendaal F.R. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 342 (2000) 696-701
16. Tripodi A. Levels of coagulation factors and venous thromboembolism. Haematologica 88 (2003) 705-711
17. de Visser M.C.H., Poort S., Vos H., Rosendaal F.R., and Bertina R.M. Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis. Thromb Haemost 85 (2001) 1011-1017
18. Sarig G., Michaeli Y., Lanir N., Brenner B., and Haim N. Mechanisms for acquired activated protein C resistance in cancer patients. J Thromb Haemost 3 (2005) 589-590
19. Kluft C., Meijer P., Gram J., and Jespersen J. Acquired activated protein-C resistance. Lancet 353 (1999) 1882
20. Chitolie A., Lawrie A.S., Mackie I.J., Harrison P., and Machin S.J. The impact of oral anticoagulant therapy, factor VIII level and quality factor V-deficient plasma on three commercial methods for activated protein C resistance. Blood Coagul Fibrinolysis 3 (2001) 179-186
21. Gennari L., Blanco A., Alberto M.F., Grosso S., Peirano A., and Lazzari M.A. Antiphospholipid antibodies impact the protein C (PC) pathway behavior. Am J Hematol 71 (2002) 128-130
22. O'Donnell J., Mumford A.D., Manning R.A., and Laffan M. Elevation of FVIII:C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost 83 (2000) 1-2
23. Faioni E.M., Franchi F., Asti D., Sacchi E., Bernardi F., and Mannucci P.M. Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay. Thromb Haemost 70 (1993) 1067-1071